Immediately preoperative use of biological therapy does not influence liver regeneration after large resection--porcine experimental model with monoclonal antibody against epidermal growth factor.

BACKGROUND The aim of this work was to study the influence of isolated biological therapy administered immediately before extended liver resection on liver function and regenerative capacity of future liver remnant (FLR) in a large-animal experiment. MATERIALS AND METHODS Nineteen piglets were included in this study (10 in the control group and 9 in the experimental group). A port-a-cath was introduced into the superior caval vein. On days 11 and 4 before liver resection, cetuximab was administered via this port at 400 mg/m2 of piglet body surface. Physiological solution was applied to the control group. Resection of the left lateral, left medial and right medial hepatic lobes was followingly performed (reduction of 50-60% of liver parenchyma). Blood samples were collected at different times before the operation and after liver resection. Serum levels of bilirubin, urea, creatinine, alkaline phosphatase, gamma glutamyltransferase, cholinesterase, aspartate aminotransferase, alanine aminotransferase, albumin, C-reactive protein and transforming growth factor-β1 were assessed. The ultrasonographic examinations at different time points were performed pre-operatively and after liver resection in order to assess the liver volume. The biopsies from the liver parenchyma were examined for proliferative activity, binocluated hepatocytes, size of hepatocytes, and the length of the lobuli. The comparison of distribution of the studied parameters between the groups was carried out using the Wilcoxon test. The Spearman rank correlation co-efficient was used because of the non-Gaussian distribution of the parameter values. The whole development of the studied parameters over time was compared between the groups using ANOVA. RESULTS There were no important complications of administration of biologic therapy during the operation or throughout the peri-operative period. There was no statistically significant difference in the regeneration of FLR nor were any differences in biochemical, immunoanalytical and histological parameters detected. CONCLUSION The achieved results of comparable liver regeneration in both the experimental and control groups confirms the use of biological treatment with cetuximab in the pre-operative period for minimizing the recovery period.

[1]  N. Fausto,et al.  Mechanisms of liver regeneration and their clinical implications. , 2005, Journal of hepato-biliary-pancreatic surgery.

[2]  J. Vauthey,et al.  Perioperative chemotherapy for resectable hepatic metastases , 2008, The Lancet.

[3]  O. Fiala,et al.  Interleukin-6 augments activation of liver regeneration in porcine model of partial portal vein ligation. , 2009, Anticancer research.

[4]  F. Giuliante,et al.  Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[6]  P. Morel,et al.  Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.

[7]  David Mangnall,et al.  The molecular physiology of liver regeneration following partial hepatectomy , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[8]  W. Jarnagin,et al.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.

[9]  C. Giovane,et al.  FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer , 2011, British Journal of Cancer.

[10]  S. Sorscher Biological therapy update in colorectal cancer , 2007, Expert opinion on biological therapy.

[11]  H. Petrowsky,et al.  Strategies for safer liver surgery and partial liver transplantation. , 2007, The New England journal of medicine.

[12]  G. Michalopoulos Liver regeneration: alternative epithelial pathways. , 2011, The international journal of biochemistry & cell biology.

[13]  J. Weitz,et al.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. , 2010, The Lancet. Oncology.

[14]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[15]  G. Poston The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  T. Pawlik,et al.  Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.

[17]  A. Panduro,et al.  Treatment with anti-tumor growth factor β antibodies influences an altered pattern of cytokines gene expression in injured rat liver , 1998 .

[18]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Hurwitz,et al.  Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. , 2008, Journal of the American College of Surgeons.

[20]  V. Paradis,et al.  Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab , 2009, Annals of Surgical Oncology.

[21]  P. Metrakos,et al.  Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[22]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Kemeny Presurgical chemotherapy in patients being considered for liver resection. , 2007, The oncologist.

[25]  H. Schlitt,et al.  Intraportal injection of porcine multipotent mesenchymal stromal cells augments liver regeneration after portal vein embolization. , 2009, In vivo.

[26]  W. Blonski,et al.  Safety of biologic therapy. , 2007, Inflammatory bowel diseases.

[27]  M. Gonen,et al.  Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study , 2007, Annals of Surgical Oncology.

[28]  Lukas Wagner,et al.  A Greedy Algorithm for Aligning DNA Sequences , 2000, J. Comput. Biol..

[29]  S. Curley,et al.  Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Michalopoulos Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. , 2010, The American journal of pathology.

[31]  P. Jeffrey,et al.  Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.

[32]  L. Rubbia‐Brandt,et al.  Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. , 2006, Journal of the American College of Surgeons.

[33]  T R Fleming,et al.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Parmar,et al.  Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Abdalla,et al.  Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases , 2008, Annals of Surgical Oncology.

[36]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. J. Haas,et al.  Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases , 2011, The British journal of surgery.

[38]  M. Ducreux,et al.  Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.